← Leaderboards
Arnold Etame
H. Lee Moffitt Cancer Ctr & Res Inst
$1,977,193
Attributed
$1,977,193
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $549.9K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,977,193 · 3
By mechanism
R01$1,091,011 · 1
R21$886,182 · 2
Top collaborators
No co-investigators on record.
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Jose R Conejo-Garcia$21,497,732
- John M Koomen$3,679,194
- Frederick Locke$1,743,048
- Eric B. Haura$11,744,471
- Andrew E Sloan$2,473,072
Others in their field
Other Emerging Leaders on “Temozolomide”
- Pier Paolo Peruzzi · Brigham And Women'S Hospital$4,140,135
- Gordon M Ringold · Quadriga Biosciences, Inc.$3,999,763
- Roger Stupp · Northwestern University At Chicago$3,204,800
- Shanshan Jiang · Johns Hopkins University$2,824,745
- Laila M Poisson · Henry Ford Health System$2,755,953
- Sean Edward Lawler · Brown University$2,609,548
Research focus
TemozolomideMalignant NeoplasmsMediatingNuclear TranslocationDesignPreventSignal TransductionTissuesPhosphorylationGlioblastomaResistanceMesenchymalRadiation TherapyMolecularMalignant - DescriptorPublishingInnovationGenesClonal EvolutionCellsBirc3 GeneHypoxiaPatient Derived Xenograft ModelApoptosis
Grant awards (5)
Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3$541,074
R01 · FY2025 · NS · contact PI
Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3$549,937
R01 · FY2024 · NS · contact PI
Exploiting Epigenetic Vulnerabilities In Glioblastoma Stem Cells Through Reprogramming$433,257
R21 · FY2022 · CA · contact PI
Modulating Glioblastoma Stem Cell Clonal Evolution Towards Therapeutic Responsiveness$205,875
R21 · FY2021 · NS · contact PI
Modulating Glioblastoma Stem Cell Clonal Evolution Towards Therapeutic Responsiveness$247,050
R21 · FY2020 · NS · contact PI